Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Opposing roles of the oncogene Akt isoforms in tumour progression: is there a dark side to Akt pathway inhibition?

Literature DB >> 23620717

Opposing roles of the oncogene Akt isoforms in tumour progression: is there a dark side to Akt pathway inhibition?

Selvaraju Veeriah¹.

Abstract

Entities: Disease Gene

Year: 2012 PMID： 23620717 PMCID： PMC3375377 DOI： 10.1007/s12154-012-0076-z

Source DB: PubMed Journal: J Chem Biol ISSN： 1864-6158

× No keyword cloud information.

28 in total

Review 1. The emerging mechanisms of isoform-specific PI3K signalling.

Authors: Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal: Nat Rev Mol Cell Biol Date: 2010-04-09 Impact factor: 94.444

Review 2. Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors: Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal: Nat Rev Drug Discov Date: 2005-12 Impact factor: 84.694

3. The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.

Authors: Y Rebecca Chin; Alex Toker
Journal: Mol Cell Date: 2010-05-14 Impact factor: 17.970

4. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.

Authors: Ioanna G Maroulakou; William Oemler; Stephen P Naber; Philip N Tsichlis
Journal: Cancer Res Date: 2007-01-01 Impact factor: 12.701

5. Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis.

Authors: J Q Cheng; D A Altomare; M A Klein; W C Lee; G D Kruh; N A Lissy; J R Testa
Journal: Oncogene Date: 1997-06-12 Impact factor: 9.867

6. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta).

Authors: H Cho; J Mu; J K Kim; J L Thorvaldsen; Q Chu; E B Crenshaw; K H Kaestner; M S Bartolomei; G I Shulman; M J Birnbaum
Journal: Science Date: 2001-06-01 Impact factor: 47.728

7. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors: Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal: Cancer Cell Date: 2004-08 Impact factor: 31.743

8. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion.

Authors: John N Hutchinson; Jing Jin; Robert D Cardiff; Jim R Woodgett; William J Muller
Journal: Cancer Res Date: 2004-05-01 Impact factor: 12.701

9. PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3.

Authors: Ingrid Remy; Annie Montmarquette; Stephen W Michnick
Journal: Nat Cell Biol Date: 2004-03-28 Impact factor: 28.824

10. A family with severe insulin resistance and diabetes due to a mutation in AKT2.

Authors: Stella George; Justin J Rochford; Christian Wolfrum; Sarah L Gray; Sven Schinner; Jenny C Wilson; Maria A Soos; Peter R Murgatroyd; Rachel M Williams; Carlo L Acerini; David B Dunger; David Barford; A Margot Umpleby; Nicholas J Wareham; Huw Alban Davies; Alan J Schafer; Markus Stoffel; Stephen O'Rahilly; Inês Barroso
Journal: Science Date: 2004-05-28 Impact factor: 47.728

3 in total